EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Eptinezumab in treatment-resistant chronic migraine: Four-year real-world effectiveness and treatment persistence

Wan-Jen Hsieh iD, Kelly Nicol, Chai Ching Ng iD, Tsung-Wei Hou, Phillip Phan, Scott W Keith, Brittany Heckel, Michael J Marmura iD, Hsiangkuo Yuan iD

Cephalalgia · 2026

DOI: 10.1177/03331024261451427 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cephalalgia, 2026. Verfasst von Wan-Jen Hsieh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Migraine Disorders, Calcitonin Gene-Related Peptide Receptor Antagonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Patient philanthropy, Miles for migraine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To evaluate 48-month real-world outcomes of eptinezumab users in chronic migraine (CM), including longitudinal effectiveness, treatment persistence, reasons for discontinuation, and post-discontinuation anti-calcitonin gene-related peptide (CGRP) treatment patterns.

Methods

We conducted a retrospective cohort study of 112 CM subjects initiating eptinezumab at a tertiary headache center between 2019 and 2021. Monthly headache days (MHD), migraine disability assessment (MIDAS), and average pain intensity (API) were extracted at baseline and every 6 months for up to 48 months using a predefined outcome form at each visit. Longitudinal changes were analyzed using generalized estimating equations (GEE) with an unstructured correlation matrix, adjusting for age, sex, and body mass index (BMI). Analyses were performed in four predefined analytic cohorts: all initiators, on-treatment, continuation, and discontinuation. Estimated marginal means (EMMs) quantified adjusted mean changes from baseline at each timepoint. No imputation or censoring for treatment discontinuation was applied. Treatment persistence, reasons for discontinuation, factors associated with discontinuation, and post-discontinuation anti-CGRP treatment patterns were summarized descriptively.

Results

Among 112 patients (mean age 50.2 ± 13.7; 77.7% female; baseline MHD median 30 [IQR 25–30]), most had failed prior anti-CGRP therapies (90.2% ≥ 1 failure; 70.6% ≥ 2 failures). In all-initiators, significant reductions in MHD were observed at 6, 18–42, corresponding to model-estimated reductions of 1.5–1.9 MHD. MIDAS increased at 6 months, corresponding to a 44-point increase, but declined over time. API improved significantly at 24, 36 and 48 months, corresponding to a 0.4–0.6-point reduction. Treatment persistence declined to 55.4%, 39.2%, 35.7%, and 29.5% at 1, 2, 3, and 4 years, respectively; the median time to discontinuation was 8 months. Ineffectiveness (34.2%), loss of effectiveness (19.0%), and insurance-related barriers (16.5%) were the most common reasons for discontinuation. After discontinuation, 54.4% initiated another anti-CGRP therapy, 26.6% stopped anti-CGRP therapy entirely, and 20.3% were lost to follow-up.

Conclusions

In this treatment-resistant CM cohort, eptinezumab produced modest but durable benefit, particularly among patients who continued treatment. Persistence declined substantially over time, and post-discontinuation care followed diverse and often complex pathways. Regular reassessment and timely adjustment of preventive strategies remain essential as clinical responses evolve. Larger prospective studies will help clarify long-term effectiveness and treatment trajectories.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersCalcitonin Gene-Related Peptide Receptor AntagonistsHumansFemaleMaleRetrospective StudiesTreatment OutcomeAdultMiddle AgedLongitudinal StudiesCohort StudiesAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

CGRP monoclonal antibodychronic migraineeptinezumablongitudinal follow-uptreatment persistence

Substanzen

eptinezumabCalcitonin Gene-Related Peptide Receptor AntagonistsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA.
  • Division of Biostatistics & Bioinformatics, Thomas Jefferson University, Philadelphia, PA, USA.

ORCID-Profile: Wan-Jen Hsieh, Chai Ching Ng, Michael J Marmura, Hsiangkuo Yuan

Förderung

  • Patient philanthropy
  • Miles for migraine

Zitieren

APA

Hsieh, W. J., Nicol, K., Ng, C. C., Hou, T. W., Phan, P., Keith, S. W., Heckel, B., Marmura, M. J., & Yuan, H. (2026). Eptinezumab in treatment-resistant chronic migraine: Four-year real-world effectiveness and treatment persistence. Cephalalgia. https://doi.org/10.1177/03331024261451427

Vancouver

Hsieh WJ, Nicol K, Ng CC, Hou TW, Phan P, Keith SW, et al. Eptinezumab in treatment-resistant chronic migraine: Four-year real-world effectiveness and treatment persistence. Cephalalgia. 2026. doi:10.1177/03331024261451427

BibTeX
@article{Hsieh2026,
  author = {Hsieh, Wan-Jen and Nicol, Kelly and Ng, Chai Ching and Hou, Tsung-Wei and Phan, Phillip and Keith, Scott W and Heckel, Brittany and Marmura, Michael J and Yuan, Hsiangkuo},
  title = {Eptinezumab in treatment-resistant chronic migraine: Four-year real-world effectiveness and treatment persistence},
  journal = {Cephalalgia},
  year = {2026},
  doi = {10.1177/03331024261451427}
}
Kostenlos starten →